Monthly Prescribing Reference
   
Subscribe to our RSS feeds RSS | Login | Register
  • HOME
  • SPECIALTY
    • Hematology-Oncology
    • Long Term Care
    • Nurse Practitioners
    • OB/GYN
    • Pharmacists
    • Physician Assistants
    • Primary Care Physicians
    • Residents
    • Urologists
  • THERAPEUTIC CATEGORIES
  • BRAND
  • GENERIC
  • COMPARE
  • NEWS
    • Drug News
    • Drugs in the Pipeline
    • Drug Safety Alerts and Recalls
    • New Drug Products
    • Polls & Surveys
    • Newsletters
    • News from Haymarket Journals
  • RESOURCES
    • Alerts (Sponsored)
    • Clinical Charts
    • Common Medical Abbreviations
    • Company
    • Drug Monograph Format
    • FDA Orange Book
    • Pharmacology Notes
    • Professional Associations
    • Video
    • Blogs
    • MPR Publications
    • Customer Service
    • Online Banner Ad Specs
    • Subscribe
  • DOWNLOAD
  • CME
  • JOBS
  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
Home > Brands > d > D-Dc
Compare | Add to Clipboard | View Clipboard
  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • D-Dc
  • Dd-De
  • Df-Di
  • Dn-Do
  • Dp-Dr
  • Ds-Dt
  • Du-Dx
  • Dy-Dz
Name Section Compare
D.H.E. 45
Pain & Pyrexia > Migraine and headache
compare
DACOGEN
Neoplasms > Antimetabolites
compare
DALMANE
Central Nervous System > Insomnia
compare
DANTRIUM
Musculoskeletal Disorders > Muscle spasms
compare
DAPTACEL
Immune System > Immunization
compare
DARVOCET A500
Pain & Pyrexia > Narcotic analgesics
compare
DARVOCET-N 100
Pain & Pyrexia > Narcotic analgesics
compare
DARVOCET-N 50
Pain & Pyrexia > Narcotic analgesics
compare
DARVON
Pain & Pyrexia > Narcotic analgesics
compare
DARVON COMPOUND 32
Pain & Pyrexia > Narcotic analgesics
compare
DARVON COMPOUND 65
Pain & Pyrexia > Narcotic analgesics
compare
DARVON-N
Pain & Pyrexia > Narcotic analgesics
compare
DAYPRO
Musculoskeletal Disorders > Arthritis/rheumatic disorders
compare
DAYQUIL COLD & FLU
Respiratory Tract > Cough and cold
compare
DAYQUIL COLD & FLU LIQUID
Respiratory Tract > Cough and cold
compare
DAYQUIL COLD & FLU PLUS VITAMIN C
Respiratory Tract > Cough and cold
compare
DAYQUIL COUGH
Respiratory Tract > Cough and cold
compare
DAYQUIL SINUS
Respiratory Tract > Cough and cold
compare
DAYTIME TRIAMINIC THIN STRIPS COLD & COUGH
Respiratory Tract > Cough and cold
compare
DAYTRANA
Central Nervous System > ADHD/narcolepsy
compare
D-VI-SOL DROPS
Nutrition > Vitamins/minerals/supplements
compare
  • Most Popular
  • Most Emailed
  • Most Recent
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Kapidex to be marketed under new trade name Dexilant
  • Hizentra approved for primary immunodeficiency
  • Xiaflex available for Dupuytren's contracture
  • Trelstar 22.5mg approved for palliative treatment of prostate cancer
  • Pediaderm HC Complete Kit available for atopic dermatitis
  • New Product: SAPHRIS® (asenapine) Sublingual Tablets
  • FDA halts marketing of unapproved nitroglycerin tablets
  • Botox approved for upper limb spasticity
  • FDA accepts NDA for lurasidone, a treatment for schizophrenia
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Recommended Adult Immunization Schedule
  • Prevnar 13 pneumococcal disease vaccine approved
  • Xiaflex available for Dupuytren's contracture
  • Hizentra approved for primary immunodeficiency
  • Kapidex to be marketed under new trade name Dexilant
  • Ampyra available for multiple sclerosis patients
  • FDA grants priority review to Tasigna for newly diagnosed chronic myeloid leukemia
  • FDA accepts NDA for JZP-6, a treatment for fibromyalgia
  • Rituxan approved for chronic lymphocytic leukemia
  • FDA halts marketing of unapproved nitroglycerin tablets
  • Hibiclens General Skin Cleansing Patient Kit available
  • Bowel Cleansers
  • Neosalus Cream available for dermatitis
  • FDA warns of reduced Plavix efficacy in poor metabolizers
  • Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Trelstar 22.5mg approved for palliative treatment of prostate cancer
  • FDA accepts NDA for lurasidone, a treatment for schizophrenia
  • FDA warns of intravascular hemolysis risk with WinRho SDF
Sponsored Links

MPR SITEMAP


Search our Drug Database

Browse by Brand
Browse by Generic
Browse by Manufacturer
Browse by Therapeutic Category

News

News
Drug News
New Drug Products
Polls & Surveys
Newsletters

Clinical Charts

Clinical Charts

Resources

Resources
Pharmacology Notes
Alerts (Sponsored)

Therapeutic Categories

Allergic Disorders
Cardiovascular System
Central Nervous System
Dental
Dermatological Disorders
Diagnostic Agents
Ear Disorders
Endocrine System
Eye Disorders
Gastrointestinal Tract
Hematology
Immune System
Infections & Infestations
Musculoskeletal Disorders
Neoplasms
Nutrition
OB/GYN
Pain & Pyrexia
Poisoning & Drug Dependence
Respiratory Tract
Urogenital System

More

Customer Service
Subscribe
Advertise
About Us
Permissions
MPR Publications
Disclaimer
Subscribe to our RSS feeds RSS


Other Haymarket Medical Websites


Cortlandt Forum

Clinical Advisor

Renal and Urology News

JAAPA

myCME - Online CME

McKnights Long Term Care News

International

healthcare republic

MIMS (drug database)
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions